<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381120</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-2010-03</org_study_id>
    <nct_id>NCT01381120</nct_id>
  </id_info>
  <brief_title>Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms</brief_title>
  <official_title>Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms (LUTS) Post Ureteroscopy for Stone Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barrie Urology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barrie Urology Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most ureteral stent insertions follow ureteroscopy procedures for stone management. Stents
      are essentially designed to prevent the blockage of the ureter. Such blockage is often a
      result of inflammation caused by ureteroscopy procedures. The stent provides a secure
      passageway for urine as it travels from the kidneys to the bladder, circumventing potential
      urinary retention. In our community, only one kind of stent is used, and it is manufactured
      by Bard. Standard protocol involves the removal of the stent 5 to 8 days following insertion.
      If stenting is required for greater than 8 days, special accommodations will be made for you
      in this study.

      Unfortunately, pain and lower urinary tract symptoms are often associated with the insertion
      and removal of stents. It is our goal to determine whether VESIcare is capable of relieving
      such symptoms.

      As a prospective member of this study, you will be asked to complete three surveys. The first
      survey will ask you about your experiences of urinary urgency and pain before your surgery.
      If you are an emergency patient, you will be asked to remember your condition before the
      surgery, completing this questionnaire at your first post-op visit. If you are not an
      emergency patient, this survey will be completed before your surgery. If your stent is
      removed within 5 to 8 days of surgery, you will be asked to complete the second survey at the
      time of removal. You will then complete the final survey at a scheduled post-operative
      check-up 4 to 5 weeks later. If your stent remains inserted for greater than 8 days after
      surgery, you will be asked to complete the second survey 3 to 4 days after your stent was
      inserted. You will then complete the final survey, 7 to 8 weeks post-op.

      Throughout this study, both VESIcare and non-VESIcare patients will be important in
      determining whether VESIcare truly is capable of relieving stent pain. As such, you will be
      randomly assigned to one of the two groups, those receiving VESIcare, and those who are not.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Post-ureteroscopy Stent-induced Pain</measure>
    <time_frame>Baseline and 3 months.</time_frame>
    <description>Measured through the use of the ureteral stent symptom questionnaire. Patients reported pain on a scale of 0 to 10 (0 being the absence of pain and 10 being the most excruciating pain of their life). The questionnaire was administered a couple days post-op and once again several weeks later. The mean difference (baseline minus 3 months) on this continuous scale was used for this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Post-ureteroscopy Stent-induced Lower Urinary Tract Symptoms.</measure>
    <time_frame>Baseline and three months.</time_frame>
    <description>Measured through the use of the ureteral stent symptom questionnaire. Patients reported symptoms on a scale of 1 to 5 (1 being the absence of symptoms and 5 being very debilitating symptoms). The questionnaire was administered a couple days post-op and once again several weeks later. The mean difference (baseline minus 3 months) on this continuous scale was used for this outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Flank Pain</condition>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>VESIcare + Narcotic Painkiller</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcotic Painkiller</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate treatment</intervention_name>
    <description>Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months</description>
    <arm_group_label>VESIcare + Narcotic Painkiller</arm_group_label>
    <other_name>VESIcare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone and acetaminophen combination treatment</intervention_name>
    <description>Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
    <arm_group_label>VESIcare + Narcotic Painkiller</arm_group_label>
    <arm_group_label>Narcotic Painkiller</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject inclusion criteria.

          1. Post-ureteroscopy for stone management.

          2. Stent inserted for more than 5 days.

          3. No significant flank pain or LUTS prior to kidney stones/stent insertion.

          4. Complete agreement with and signing of Informed Consent form.

        Subject exclusion criteria.

          1. Significant flank pain or LUTS prior to kidney stones/stent insertion.

          2. Currently taking antimuscarinics or Î±1 blockers.

          3. Patients with urinary retention, dependent on dialysis, gastroparesis or narrow angle
             glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Zadra, MD CM FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrie Urology Associates - The Male/Female Health and Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrie Urology Associates - The Male/Female Health and Research Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Mendez-Probst CE, Fernandez A, Denstedt JD. Current status of ureteral stent technologies: comfort and antimicrobial resistance. Curr Urol Rep. 2010 Mar;11(2):67-73. doi: 10.1007/s11934-010-0091-y. Review.</citation>
    <PMID>20425092</PMID>
  </reference>
  <reference>
    <citation>Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res. 2009 Jun;37(3):147-52. doi: 10.1007/s00240-009-0182-8. Epub 2009 Mar 10.</citation>
    <PMID>19277623</PMID>
  </reference>
  <reference>
    <citation>Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008 Apr;22(4):651-6. doi: 10.1089/end.2007.0257.</citation>
    <PMID>18338955</PMID>
  </reference>
  <reference>
    <citation>Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009 Nov;23(11):1913-7. doi: 10.1089/end.2009.0173.</citation>
    <PMID>19814699</PMID>
  </reference>
  <reference>
    <citation>Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4.</citation>
    <PMID>12576846</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>February 9, 2012</results_first_submitted>
  <results_first_submitted_qc>July 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2012</results_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barrie Urology Associates</investigator_affiliation>
    <investigator_full_name>Dr. Joseph Zadra</investigator_full_name>
    <investigator_title>Chief of Urology, RVH</investigator_title>
  </responsible_party>
  <keyword>Flank Pain</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>LUTS</keyword>
  <keyword>Urgency</keyword>
  <keyword>Nocturia</keyword>
  <keyword>Frequency</keyword>
  <keyword>Ureteroscopy</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>Stent</keyword>
  <keyword>Incontinence</keyword>
  <keyword>VESIcare</keyword>
  <keyword>Ureter</keyword>
  <keyword>Urinary Bladder, Overactive</keyword>
  <keyword>OAB</keyword>
  <keyword>Overactive Bladder Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Flank Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Narcotics</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VESIcare + Narcotic Painkiller</title>
        </group>
        <group group_id="P2">
          <title>Narcotic Painkiller</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VESIcare + Narcotic Painkiller</title>
        </group>
        <group group_id="B2">
          <title>Narcotic Painkiller</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.81" spread="12.36"/>
                    <measurement group_id="B2" value="57.54" spread="18.73"/>
                    <measurement group_id="B3" value="53" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Post-ureteroscopy Stent-induced Pain</title>
        <description>Measured through the use of the ureteral stent symptom questionnaire. Patients reported pain on a scale of 0 to 10 (0 being the absence of pain and 10 being the most excruciating pain of their life). The questionnaire was administered a couple days post-op and once again several weeks later. The mean difference (baseline minus 3 months) on this continuous scale was used for this outcome measure.</description>
        <time_frame>Baseline and 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VESIcare + Narcotic Painkiller</title>
            <description>VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
          </group>
          <group group_id="O2">
            <title>Narcotic Painkiller</title>
            <description>Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post-ureteroscopy Stent-induced Pain</title>
          <description>Measured through the use of the ureteral stent symptom questionnaire. Patients reported pain on a scale of 0 to 10 (0 being the absence of pain and 10 being the most excruciating pain of their life). The questionnaire was administered a couple days post-op and once again several weeks later. The mean difference (baseline minus 3 months) on this continuous scale was used for this outcome measure.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" lower_limit="3.75" upper_limit="5.46"/>
                    <measurement group_id="O2" value="3.11" lower_limit="1.63" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Post-ureteroscopy Stent-induced Lower Urinary Tract Symptoms.</title>
        <description>Measured through the use of the ureteral stent symptom questionnaire. Patients reported symptoms on a scale of 1 to 5 (1 being the absence of symptoms and 5 being very debilitating symptoms). The questionnaire was administered a couple days post-op and once again several weeks later. The mean difference (baseline minus 3 months) on this continuous scale was used for this outcome measure.</description>
        <time_frame>Baseline and three months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VESIcare + Narcotic Painkiller</title>
            <description>VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
          </group>
          <group group_id="O2">
            <title>Narcotic Painkiller</title>
            <description>Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post-ureteroscopy Stent-induced Lower Urinary Tract Symptoms.</title>
          <description>Measured through the use of the ureteral stent symptom questionnaire. Patients reported symptoms on a scale of 1 to 5 (1 being the absence of symptoms and 5 being very debilitating symptoms). The questionnaire was administered a couple days post-op and once again several weeks later. The mean difference (baseline minus 3 months) on this continuous scale was used for this outcome measure.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.60" upper_limit="2.21"/>
                    <measurement group_id="O2" value="1.13" lower_limit="0.82" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the duration of the study (October 2010 - June 2012)</time_frame>
      <desc>Non-serious events were not recorded. Patients were encouraged to contact the study coordinator if they experienced any serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>VESIcare + Narcotic Painkiller</title>
        </group>
        <group group_id="E2">
          <title>Narcotic Painkiller</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Zadra</name_or_title>
      <organization>Barrie Urology Associates</organization>
      <email>joezadra@rogers.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

